{
    "nctId": "NCT01982591",
    "briefTitle": "Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy",
    "officialTitle": "Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Male Breast Cancer, Neurotoxicity, Peripheral Neuropathy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 115,
    "primaryOutcomeMeasure": "Level of heavy metal in blood and urine",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have histologically confirmed invasive mammary carcinoma; any histologic sub-type allowed\n* Patients must be diagnosed with stage I, II or III breast cancer\n* Patients must be undergoing treatment with an adjuvant or neoadjuvant cytotoxic chemotherapy that includes a taxane, specifically paclitaxel, nab-paclitaxel (Abraxane), or docetaxel\n* Patients may have received prior endocrine and/or radiation therapy\n* Patients must have the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients who have been previously treated with cytotoxic chemotherapy\n* Patients with pre-existing peripheral neuropathy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}